Atlas Trials

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Clinical trial NCT03270007 · UNKNOWN

Trial details

NCT number
NCT03270007
Sponsor
Tao OUYANG
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Primary Breast Cancer
Start date
2017-11-10
Primary completion
2024-06-30
Enrollment
304

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.